newsfilter
← Latest News
GlobeNewswire·

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

  • RenovoRx, Inc. (NASDAQ: RNXT) received a Notice of Allowance from the USPTO for patent application 18/184,620 covering methods & apparatuses for delivering therapeutic materials to treat cancer.
  • This allowance strengthens the company's U.S. intellectual property portfolio, expanding protection for its TAMP™ platform & RenovoCath dual-occlusion catheter device.
  • The allowed claims cover the proprietary catheter system, which includes a primary catheter, multiple ports, & expandable occlusion balloons to create controlled treatment zones for targeted drug delivery.
  • RenovoRx's global intellectual property portfolio now totals 20 issued or allowed patents & 13 pending patents related to the TAMP platform & RenovoCath device.
  • CEO Shaun Bagai stated the allowance reinforces the company's competitive differentiation & supports the commercialization strategy & ongoing Phase III TIGeR-PaC clinical trial.
  • RenovoCath is an FDA-cleared device intended for isolating blood flow & delivering fluids to peripheral vascular sites, including temporary vessel occlusion for arteriography & chemotherapeutic infusion.
  • In 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with a record year-to-date sale of $1.5 million as of June 30, 2026.
  • The company is evaluating its investigational intra-arterial gemcitabine product (IAG) delivered via RenovoCath in the Phase III TIGeR-PaC trial, with full enrollment anticipated in the near term & data readout expected in mid-to-late 2027.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, providing seven years of market exclusivity upon FDA approval.
  • RenovoRx is actively expanding orders from high-volume National Cancer Institute-designated centers to increase the adoption of its RenovoCath device.